Business
Pulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse Stimulation
Strategic focus shifting to advance core NPS™ technology in cardiac and oncology sectors, activate additional executive leadership and reduce dermatologic
About this update from Pulse Biosciences, Inc
[{"type":"text","content":"\nStrategic focus shifting to advance core NPS™ technology in cardiac and oncology sectors, activate additional executive leadership and reduce dermatologic footprint.\n\nFormer Chief Commercial Officer, Kevin Danahy, appointed Chief Executive Officer; Former Chief Executive Officer Darrin Uecker to serve as Chief Technology Officer; Robert W. Duggan appointed as Executive Chairman; Joe Talarico to assume VP Business Development position.\n\nRobert Duggan and the Company enter into a $65 Million Loan Agreement.\n\n HAYWARD, Calif.--(BUSINESS WIRE)--\nPulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced a shift in focus to advance its core technology. Pulse Biosciences is expanding strategic opportunities within healthcare, and anticipates a concentrated focus on cardiovascular applications, with potential expansion in oncology, gastroenterology, and other sectors where the Company has established key opinion leader relationships and emerging preclinical evidence.\n\nTo support the realignment, Pulse Biosciences has made several executive team changes. Kevin Danahy, who served as Chief Commercial Officer since February, is succeeding Darrin Uecker as President and Chief Executive Officer. The Company is very pleased to announce that Mr. Uecker will devote his full time to the newly created role of Chief Technology Officer where he will be responsible for technology advancement and product development. Joe Talarico, who currently serves as Vice-President of North American Sales, will become Vice-President of Business Development where he will leverage his significant experience in the commercial introduction of new disruptive technologies. Board Chairman, Robert Duggan, will assume a newly created leadership role as the Company’s Executive Chairman.\n\n“During his time at Pulse, Kevin has demonstrated strong leadership and operational skills. The Board of Directors believes he is the right person to lead Pulse during this next pivotal phase. I am confident in NPS technology and its potential,” said Robert Duggan, Executive Chairman of Pulse Biosciences. “We have positioned the Company to now focus on high opportunity application areas.”\n\nImplementing the present time strategic opportunities does not re...